ReviewCurrent rheumatology reports2020
Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis.Rheumatology international · 2021Pooled it
- Diagnostic Challenges and Modern Therapeutic Strategies in Giant Cell Arteritis.Diagnostics (Basel, Switzerland) · 2026Review
- Treatment and evolution of 134 patients with aortitis and periaortitis: experience of a third-level university hospital.Internal and emergency medicine · 2026Observational
- Integrated bulk and single-cell transcriptomics identifies shared and specific immune signatures in Takayasu Arteritis.Arthritis research & therapy · 2025Article
- Premaxillary Fat Pads on Magnetic Resonance Imaging (MRI) as a Marker of Steroid Side Effects.Cureus · 2025Article
- Article
- Biopsy-Confirmed Small Vessel Primary CNS Vasculitis: Clinical Features and Impact of Early Intensive Treatment on Remission.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Gene variants of glucocorticoid activation pathways and the outcomes of patients with Takayasu arteritis - a retrospective cohort study.Frontiers in immunology · 2025Article
- Bridging Gaps and Charting Future Directions in Vasculitis.Journal of clinical medicine · 2024Article
- Comparing Diagnostic Performance of Short and Long [Diagnostics (Basel, Switzerland) · 2023Article
- Azathioprine-induced lymphoma in a patient with Takayasu arteritis: A case report from Iraq.Clinical case reports · 2023Article
- Optimizing the use of temporal artery biopsy: a retrospective study.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023Article
- Perspectives of JAK Inhibitors for Large Vessel Vasculitis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile glucocorticoids (GCs) are effective in large vessel vasculitis (LVV), they may cause serious adverse events (AEs), especially if taken for longer durations and at higher doses. Unfortunately, patients suffering from LVV often need long-term treatment with GCs; therefore, toxicity needs to be expected and countered. RECENT
findingsGCs remain the mainstay of therapy for both giant cell arteritis and Takayasu arteritis. In order to minimize their toxicity, the following strategies should be considered: GC tapering, administration of conventional synthetic (e.g., methotrexate) or biologic (e.g., tocilizumab) GC-sparing agents, as well as monitoring, prophylaxis, and treatment of GC-related AEs. Several drugs are currently under investigation to expand the armamentarium for the treatment of LVV. GC treatment in LVV is effective but associated with toxicity. Strategies to minimize this toxicity should be applied when treating patients suffering from LVV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.